Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
93.83
+0.40 (0.43%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 91.56 - 95.36
52 week 47.03 - 111.49
Open 92.56
Vol / Avg. 1.03M/850,246.00
Mkt cap 7.75B
P/E     -
Div/yield     -
EPS -5.37
Shares 82.59M
Beta 1.67
Inst. own 74%
Feb 11, 2015
Q4 2014 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 10, 2015
Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - 11:00AM EST - Add to calendar
Feb 5, 2015
Alnylam Pharmaceuticals Inc at Emerald Research Groundhog Day Investment Forum - 1:35PM EST - Add to calendar
Jan 12, 2015
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference
Jan 12, 2015
Alnylam Pharmaceuticals Inc Reports Initial Evidence for Potential Correction of the Hemophilia Phenotype in Phase 1 Study of ALN-AT3
Dec 12, 2014
Alnylam Pharmaceuticals Inc R&D Day
Dec 11, 2014
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference
Dec 3, 2014
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Dec 2, 2014
Alnylam Pharmaceuticals Inc at Deutsche Bank BioFEST
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -400.92% -189.17%
Operating margin -411.95% -197.05%
EBITD margin - -175.36%
Return on average assets -17.48% -25.20%
Return on average equity -19.11% -44.13%
Employees 165 -
CDP Score - -

Address

3rd Floor, 300 Third Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi) in the United States. The Company�s Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia; ALN-TMP for the treatment of iron overload; ALN-CC5 for the treatment of C5 complement component mediated diseases, and GalNAc Conjugates. The Company has three partner-based programs in clinical or pre-clinical development, including ALN-RSV01, ALN-VSP and ALN-HTT for the treatment of Huntington�s disease (HD). As of March 2014, the Company acquired Merck's subsidiary Sirna Therapeutics, Inc.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 39
Bio & Compensation  - Reuters
Michael W. Bonney Director
Bio & Compensation  - Reuters
Amy W. Schulman Director
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 60
Bio & Compensation  - Reuters